Zydus Pharmaceuticals Inc Succinylcholine Chloride Injection, USP 200 mg/10 mL recall: Failed Impurities/Degradation Specifications: Out-of-Specification test
Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity.
The hazard: Sterility or particulate concern
This recall is about sterility assurance. It does not mean every unit is contaminated — it means the manufacturer cannot demonstrate that none of them is.
What the notice says: Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity.
Why it matters: The product was made or packaged in conditions that cannot assure sterility, or visible particles were found in it. For anything injected, infused or used in the eye, that is a direct route for contamination into the body.
Symptoms and when to call a doctor
Watch for fever, chills, pain, redness, swelling or discharge at an injection site, and for a red, painful or suddenly blurred eye after using an eye product. Any of these needs same-day medical attention. Do not wait to see whether it settles, and tell the clinician which product and lot you used so it can be reported against the recall.
This page is general information, not medical advice. If you feel unwell, a clinician who can see you is the only person able to judge your case.
Recall details
- Recall number
- D-0623-2025
- Published
- September 17, 2025
- Risk level
- Class II
- Status
- Ongoing
- Issued by
- U.S. Food and Drug Administration
- Brand
- Zydus Pharmaceuticals Inc
- Product type
- Prescription & OTC drugs
- Units affected
- 270,125 Vials
- Distribution
- Louisiana, Mississippi, Ohio, Puerto Rico
- Made in
- United States
- Lot / code info
- Lot #s: L400077, exp: 8/31/2025; L400113, exp.: 9/30/2025; L400372, L400373, exp.: 3/31/2026; L400374, exp.: 4/30/2026.
Products covered by this recall
Succinylcholine Chloride Injection, USP 200 mg/10 mL (20 mg/mL), Rx only, 10 mL Multiple-dose Vial, Sterile, Manufactured by Zydus Lifesciences Ltd, Vadodara, India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1377-1 (vial), NDC 70710-1377-2 (carton).
Check your product
The notice names 8 codes you can read straight off the package. Type the one printed on yours and the list below narrows to it.
Lot or batch code
Usually ink-stamped near the seam, the cap or the bottom of the pack.
- L400077
Best-by / use-by date
Printed beside the lot code, not on the price sticker.
- 31
- 2025
NDC number
On the carton and again on the bottle or blister label.
- 70710-1377-1
- 70710-1377-2
Package size
Match the net weight or the piece count on the front of the pack.
- 200 mg
- 10 mL
- 20 mg
Codes are lifted verbatim from the FDA — Drug enforcement notice. A code that is missing here may still be covered — the official notice is the complete list.
What to do about Sterility
Zydus Pharmaceuticals Inc — This recall is about sterility assurance. It does not mean every unit is contaminated — it means the manufacturer cannot demonstrate that none of them is.
- Stop using the affected lot and check the lot number on your own carton or vial against the codes listed above.
- Call your prescriber or pharmacy today about a replacement from an unaffected lot — do not simply skip doses of a medicine you depend on.
- If you are a clinic or pharmacy, quarantine the stock and work it through your usual recall log.
- Report any infection or reaction you think the product caused to FDA MedWatch.
Refunds and replacements
With medicines, a replacement supply matters more than cash, and that is what pharmacies are set up to provide.
- Ask the dispensing pharmacy for a like-for-like replacement from an unaffected lot. This is the fastest route and usually costs nothing.
- For a mail-order or online pharmacy, use the recall line listed on this page rather than the general support queue.
- If the recall voided a fill you had already paid for, your insurer will normally authorise a replacement ahead of schedule. Quote the recall number.
- If you paid out of pocket, ask for a refund of the co-pay or purchase price and keep the receipt the pharmacy issues.
Company contact: Zydus Pharmaceuticals (USA) Inc — 73 Route 31 N, Pennington, NJ, 08534-3601
The official notice
This page summarises a notice published by U.S. Food and Drug Administration. The agency notice is the authoritative version — read it before you act, and treat it as the final word if anything here looks different.
Open the FDA — Drug enforcement record U.S. Food and Drug Administration recalls
Questions people ask about this recall
Why was Zydus Pharmaceuticals Inc prescription & otc drugs recalled?
Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity. Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity.
How do I know if I have the recalled product?
Match the codes printed on your package against the notice: lot code L400077; best-by date 31 or 2025. If the code on your package is not on that list, your unit is outside the recall.
What should I do with it right now?
Stop using the affected lot and check the lot number on your own carton or vial against the codes listed above.
Can I get my money back?
Ask the dispensing pharmacy for a like-for-like replacement from an unaffected lot. This is the fastest route and usually costs nothing.
Which states were affected?
The notice lists Louisiana, Mississippi, Ohio, Puerto Rico.
Related recalls
-
Class II · 2 months ago
Zydus Pharmaceuticals Inc Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle recall: CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron
CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.
-
Class II · 5 months ago
Zydus Pharmaceuticals Inc Erythromycin Tablets, USP, 500 mg, 30 tablets per bottle recall: CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
-
Class II · 5 months ago
Zydus Pharmaceuticals Inc Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle recall: CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
-
Class II · 7 months ago
Zydus Pharmaceuticals Inc Icosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle recall: Failed Tablet/Capsule specifications: Red dots inside capsule and melted
Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.
-
Class II · 9 months ago
Zydus Pharmaceuticals Inc Icosapent Ethyl capsules, 1 gram, 120-count bottles recall: Subpotent Drug: Due to oxidation caused by leakage of the contents
Subpotent Drug: Due to oxidation caused by leakage of the contents of the capsules
-
Class III · 10 months ago
Zydus Pharmaceuticals Inc traZodone Hydrochloride Tablets, USP, 100mg, 1,000 Tablets recall: Failed Tablet/Capsule Specifications: Product complaint received that some
Failed Tablet/Capsule Specifications: Product complaint received that some tablets had a dent on the plain side of the tablet surface.